Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

NCT07644481 | Not Yet Recruiting DMC

• 1 other identifier: IIT2026038
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single-center, prospective, exploratory clinical study. It plans to enroll 30 adult patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR1) after induction therapy and meet the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The aim is to evaluate the efficacy and safety of allo-HSCT following conditioning regimens with clofarabine, busulfan and melphalan.

Conditions

AML (Acute Myelogenous Leukemia); Allogeneic Hematopoietic Stem Cell Transplantation Recipient

Outcome Measures

Primary Outcomes (1)

• 2-year Overall Survival（OS）rate

  2 years.

Secondary Outcomes (8)

• 1-year Overall Survival（OS）rate

  1 year

• 1-year Relapse-Free Survival(RFS) rate,2-years Relapse-Free Survival(RFS) rate

  1-year,2-years

• Day 100 non-relapse mortality (NRM) rate after transplantation

  as the non-relapse mortality at Day 100 post-transplantation.

• 2-year cumulative incidence of relapse (CIR) after transplantation

  2-year

• Minimal Residual Disease(MRD) negative conversion rate

  Bone marrow MRD levels are monitored at 1, 3, 6, 9 and 12 months after hematopoietic stem cell transplantation.

Study Arms (1)

Planned to enroll adult patients with acute myeloid leukemia (AML) who achieve first complete remiss

EXPERIMENTAL

Drug: CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen

Interventions

CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen DRUG

CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen

Planned to enroll adult patients with acute myeloid leukemia (AML) who achieve first complete remiss

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Aged from 18 to 60 years inclusive, with no restriction on gender;
• Patients diagnosed with acute myeloid leukemia (AML, excluding acute promyelocytic leukemia, APL) by bone marrow morphological, immunological and genetic examinations according to the 2022 World Health Organization (WHO) classification, who have achieved first complete remission (CR1) after induction therapy;
• Meeting any of the following criteria upon clinical evaluation:
• AML classified as intermediate or adverse genetic risk according to the 2022 ELN genetic risk stratification;
• AML with positive measurable residual disease (MRD) before transplantation;
• Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-2;
• Estimated survival time more than 6 months;
• Meeting the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT), and having an eligible hematopoietic stem cell donor with qualified physical examination, including HLA-matched sibling donor, unrelated donor (high-resolution HLA 9-10/10 matched) or haploidentical related donor;
• Adequate major organ function meeting the following criteria:
• Total bilirubin (TBIL) ≤ 2 times the upper limit of normal (ULN); Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3 × ULN;
• Serum creatinine (Cr) ≤ 1.5 × ULN, or estimated creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault glomerular filtration formula;
• Coagulation function meeting the following standards: Prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulant therapy);
• Electrocardiogram showing no acute myocardial infarction or severe arrhythmia; Echocardiography with left ventricular ejection fraction (LVEF) ≥ 50%, without significant cardiomegaly, valvular heart disease or congenital heart disease;
• Pulmonary function tests: FEV1, FVC and DLCO ≥ 60% of predicted value;
• Willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy prior to study treatment, and agree to receive regular bone marrow aspiration and biopsy after study treatment;

You may not qualify if:

• Refractory/relapsed AML;
• Known hypersensitivity to any drugs in the conditioning regimen or their excipients;
• Major surgery within the past 4 weeks (excluding diagnostic surgical procedures);
• History of or concurrent other malignant tumors (excluding well-controlled non-melanoma basal cell carcinoma of the skin, breast/cervical carcinoma in situ, and other malignancies well controlled without treatment for more than five years);
• \. Uncontrolled systemic diseases (such as uncontrolled hypertension, diabetes mellitus, etc.);
• Active hepatitis B or hepatitis C infection:（Hepatitis B virus surface antigen positive, hepatitis B core antibody positive with HBV-DNA level exceeding 1×103 copies/mL;Hepatitis C virus RNA level exceeding 1×10 3 copies/mL）;
• Uncontrolled ongoing infection, or patients requiring mechanical ventilation or with hemodynamic instability;
• Patients with psychiatric disorders or other medical conditions who are unable to comply with study treatment and monitoring requirements;
• Participation in another ongoing clinical trial, or enrollment in any other drug clinical trial within the past 1 month;
• Pregnant or lactating females, and patients who refuse to use effective contraception during the study period;
• Patients who are unable to understand the trial protocol, adhere to medication instructions, or refuse to sign the informed consent form;
• Patients deemed ineligible for enrollment by the investigator.

Sponsors & Collaborators

• Institute of Hematology & Blood Diseases Hospital, China: lead

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Busulfan; Melphalan; Transplantation Conditioning

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Butylene Glycols; Glycols; Alcohols; Organic Chemicals; Mesylates; Alkanesulfonates; Alkanesulfonic Acids; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Immunosuppression Therapy; Immunotherapy; Immunomodulation; Biological Therapy; Therapeutics; Immunologic Techniques; Investigative Techniques

Central Study Contacts

Erlie Jiang

CONTACT

+86-15122538106; jiangerlie@ihcams.ac.cn

Xiaoyu Zhang

CONTACT

+86-18202579691; zhangxiaoyu@ihcams.ac.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 10, 2026
• First Posted: June 12, 2026
• Study Start (Estimated): July 20, 2026
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: June 12, 2026

Record last verified: 2026-06